Study investigates diverse molecular mechanisms driving treatment resistance in AML
February 06, 2019
A Nature Communications study led by Jeff Tyner, Ph.D., suggests comprehensive mutational sequencing should be carried out on patient samples at the beginning and throughout treatment for acute myeloid leukemia (AML).